Showing 13 to 24 of 44 results
Chinese Biotech Firm's Lung Cancer Breakthrough Shakes Up Global Pharma Industry
Akeso, a Chinese biotech firm, surprised the world by decisively beating Merck's leading lung cancer drug in clinical trials, marking a significant shift in global pharmaceutical innovation from the US to China, attracting major investments and raising concerns in the US.
Chinese Biotech Firm's Lung Cancer Breakthrough Shakes Up Global Pharma Industry
Akeso, a Chinese biotech firm, surprised the world by decisively beating Merck's leading lung cancer drug in clinical trials, marking a significant shift in global pharmaceutical innovation from the US to China, attracting major investments and raising concerns in the US.
Progress
44% Bias Score
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
Progress
40% Bias Score
NIH Budget Cuts Threaten Life-Saving Cancer Research
The Trump administration's proposed 44% cut to the NIH budget, resulting in over 1,000 job losses, threatens to halt life-saving clinical trials, sparking bipartisan outrage in Congress and public disapproval, as evidenced by a recent poll showing 77% opposition to such cuts.
NIH Budget Cuts Threaten Life-Saving Cancer Research
The Trump administration's proposed 44% cut to the NIH budget, resulting in over 1,000 job losses, threatens to halt life-saving clinical trials, sparking bipartisan outrage in Congress and public disapproval, as evidenced by a recent poll showing 77% opposition to such cuts.
Progress
60% Bias Score
VA Research Budget Cuts Threaten Medical Innovation and Veteran Care
The U.S. Department of Veterans Affairs faces potential cuts to its nearly $1 billion medical research budget, threatening thousands of researchers and jeopardizing ongoing projects vital to veteran care and broader medical innovation, including a large genetic study of a million veterans.
VA Research Budget Cuts Threaten Medical Innovation and Veteran Care
The U.S. Department of Veterans Affairs faces potential cuts to its nearly $1 billion medical research budget, threatening thousands of researchers and jeopardizing ongoing projects vital to veteran care and broader medical innovation, including a large genetic study of a million veterans.
Progress
48% Bias Score
Aspirin Shows Promise in Cancer Fight: Animal Study
Aspirin, a common pain reliever, shows promise in fighting cancer by enhancing the immune system's ability to destroy spreading cancer cells, according to a University of Cambridge animal study, though human trials are needed to confirm its efficacy and safety.
Aspirin Shows Promise in Cancer Fight: Animal Study
Aspirin, a common pain reliever, shows promise in fighting cancer by enhancing the immune system's ability to destroy spreading cancer cells, according to a University of Cambridge animal study, though human trials are needed to confirm its efficacy and safety.
Progress
40% Bias Score
US Research Funding Cuts Disrupt Global Health Initiatives
The US government's abrupt cuts to research funding have left 1350 local employees in two HIV projects unemployed, disrupted treatment for infectious diseases, jeopardized ongoing clinical trials, and created a climate of fear within the scientific community, with wide-ranging implications for globa...
US Research Funding Cuts Disrupt Global Health Initiatives
The US government's abrupt cuts to research funding have left 1350 local employees in two HIV projects unemployed, disrupted treatment for infectious diseases, jeopardized ongoing clinical trials, and created a climate of fear within the scientific community, with wide-ranging implications for globa...
Progress
60% Bias Score
iPSC-Based Therapies Show Promise in Treating Diabetes and Parkinson's Disease
Recent studies show iPSC-derived cells successfully treated diabetes and Parkinson's disease in small clinical trials, offering hope for regenerative medicine, although challenges in cost and scalability remain.
iPSC-Based Therapies Show Promise in Treating Diabetes and Parkinson's Disease
Recent studies show iPSC-derived cells successfully treated diabetes and Parkinson's disease in small clinical trials, offering hope for regenerative medicine, although challenges in cost and scalability remain.
Progress
36% Bias Score
BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported
BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.
BioNTech's Oncology Push: Cancer Drug Filing Planned, Q1 Loss Reported
BioNTech, experiencing a €415.8 million net loss in Q1 2025, plans to file for U.S. approval of a uterine cancer treatment by year-end, aiming to become a leading oncology company by 2030, with a new CFO starting July 1st, 2025.
Progress
36% Bias Score
New HHS Vaccine Rule Risks Delaying Fall Covid-19 Booster Rollout
HHS Secretary Robert F. Kennedy Jr.'s new rule mandates placebo-controlled trials for all new vaccines, potentially delaying the fall rollout of updated Covid-19 vaccines from Pfizer and Moderna by months, according to vaccine experts, due to the time needed for new trials and analysis; the FDA is e...
New HHS Vaccine Rule Risks Delaying Fall Covid-19 Booster Rollout
HHS Secretary Robert F. Kennedy Jr.'s new rule mandates placebo-controlled trials for all new vaccines, potentially delaying the fall rollout of updated Covid-19 vaccines from Pfizer and Moderna by months, according to vaccine experts, due to the time needed for new trials and analysis; the FDA is e...
Progress
64% Bias Score
China Begins Phase I Trials for First Mpox Vaccine Candidate
China's first mpox vaccine candidate, an MVA strain developed by the Shanghai Institute of Biological Products, has started Phase I clinical trials in Zhengzhou, involving 120 participants from high-risk groups, aiming to accelerate mpox prevention in China and globally.
China Begins Phase I Trials for First Mpox Vaccine Candidate
China's first mpox vaccine candidate, an MVA strain developed by the Shanghai Institute of Biological Products, has started Phase I clinical trials in Zhengzhou, involving 120 participants from high-risk groups, aiming to accelerate mpox prevention in China and globally.
Progress
20% Bias Score
Brain Cancer Recurrence Prompts Clinical Trial
Professor Richard Scolyer, a 58-year-old Australian of the Year, faces potential recurrence of his aggressive brain cancer after a recent scan; surgery is scheduled for Monday to assess and potentially remove the tumor, though his prognosis remains 3-6 months, following an experimental treatment tha...
Brain Cancer Recurrence Prompts Clinical Trial
Professor Richard Scolyer, a 58-year-old Australian of the Year, faces potential recurrence of his aggressive brain cancer after a recent scan; surgery is scheduled for Monday to assess and potentially remove the tumor, though his prognosis remains 3-6 months, following an experimental treatment tha...
Progress
24% Bias Score
Phase One Clinical Trial Begins for Novel Russian Oncolytic Virus Cocktail
The Herzen Institute in Moscow has begun phase one clinical trials of a new Russian-made oncolytic virus cocktail for breast cancer treatment, involving 38 patients and showing promise in pre-clinical trials, with plans to expand to glioblastoma and other cancer types in later phases.
Phase One Clinical Trial Begins for Novel Russian Oncolytic Virus Cocktail
The Herzen Institute in Moscow has begun phase one clinical trials of a new Russian-made oncolytic virus cocktail for breast cancer treatment, involving 38 patients and showing promise in pre-clinical trials, with plans to expand to glioblastoma and other cancer types in later phases.
Progress
56% Bias Score
Showing 13 to 24 of 44 results